Wellington Partners Maintains Medtech Interests With New €210M Eurocentric Fund WPLS-V
While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.
You may also be interested in...
Adrenomed’s chief business officer Frauke Hein explained to Mike Ward how the company has moved from establishing a diagnostic marker for septic shock to developing a therapeutic candidate.
Belgian drug discovery company raises funds to finance development of its platform to discover compounds targeting difficult-to-drug GPCRs and advance lead program to the clinic.
A Danish company with a novel approach to gene editing for antibacterials has raised $50m in a series A round, using the cash injection to advance its ambition to be testing drug candidates in humans by 2021.